Taiwan's post-pandemic Mycoplasma surge: incidence doubled, brain complications up 13-fold

The bacterial causes of childhood pneumonia came back on different schedules after the pandemic. Mycoplasma pneumoniae did not reemerge as quickly as influenza or respiratory syncytial virus, probably because of its long incubation period, long periodicity and slow growth rate — and then, from mid-2023, it rebounded hard, driving unprecedented epidemics across multiple countries [s1].

A new multicentre surveillance study from Taiwan, published in Emerging Infectious Diseases, quantifies how hard, and pairs the clinical numbers with genome sequencing that shows the underlying organism has changed.

Incidence, intensive care and the brain

The study drew on the laboratory surveillance system of Chang Gung Memorial Hospital, spanning four branches — Linkou, Taipei, Tucheng and Kaohsiung — one of the largest healthcare networks in Taiwan, and compared eight seasons from 2017 through 2024 in children under 18 [s1].

Compared with the 2019 pre-pandemic peak, the 2024 data showed a doubling of incidence, to 546 per 100,000 population [s1]. Intensive care unit admissions rose 2.2-fold, to 10.9 per 100,000, and central nervous system complications surged 13.7-fold, to 6.1 per 100,000 [s1]. Those neurological syndromes — defined as events confirmed by PCR detection of M. pneumoniae and without an alternative cause — included encephalitis, acute disseminated encephalomyelitis, Guillain-Barré syndrome and transverse myelitis [s1].

That last multiple is the one that stands out. A thirteen-fold rise in brain and nerve complications is a different kind of signal from a rise in case counts, because it suggests the resurgence is not only larger but, by some measure, more severe.

Who ended up in intensive care

To find out which children were at risk, the team extended a prospective cohort of 226 children with laboratory-confirmed infection during 2023–2024 [s1].

Four factors were independently associated with ICU admission: a neutrophil count above 7,000 per microlitre (adjusted odds ratio 6.2, 95% CI 1.3–29.9), a platelet count above 400,000 per microlitre (aOR 12.5, 2.7–57.9), pleural effusion (aOR 9.7, 1.6–58.1), and central nervous system involvement (aOR 27.9, 4.1–188.3) [s1]. The wide confidence intervals reflect a modest cohort, but the direction is consistent: inflammation, fluid on the lungs and neurological signs mark the children who deteriorate.

The organism changed

The second half of the study is what separates it from a simple case count. Phylogenetic analysis of 698 genomes showed that four emerging subclades had replaced the pre-pandemic lineages by mid-2024, and one of those subclades was associated with severe outcomes [s1].

That matters because of Taiwan's resistance background. M. pneumoniae there carries high rates of macrolide resistance — reaching 70 percent before the pandemic [s1]. The authors frame their findings as evidence of evolving resistant, neurotropic lineages, and call for enhanced surveillance [s1].

The global context

The picture elsewhere is uneven. In parts of Europe and the United States, where macrolide resistance stays below 10 percent, severe paediatric cases rose in Spain, England and Texas, but not in the Netherlands, Norway or Denmark [s1]. France and Switzerland documented high rates of ICU admission among adults [s1]. A highly publicised outbreak in China was notable for an exceptionally high macrolide resistance rate of 90 to 100 percent and a substantial burden of severe disease, primarily in children [s1].

Against that backdrop, whether prolonged fever and complications track specifically with macrolide resistance has not been consistently demonstrated — but M. pneumoniae is increasingly associated with severe illness regardless of resistance, and the role of the pathogen's genetic evolution in that trend remains unclear [s1].

What the study cannot tell you

Diagnostic testing across the four branches was clinician-driven, ordered for children with compatible signs, so the incidence estimates reflect tested, care-seeking children rather than a community census [s1]. The cohort analysis of ICU risk factors is observational and modest in size. And the link between the newly dominant subclades and severe outcomes is an association drawn from sequencing, not proof that the lineages are intrinsically more dangerous.

What to watch

Whether the four subclades that took over by mid-2024 persist into later seasons, and whether the severe-outcome subclade spreads beyond Taiwan [s1]. The study documents a resurgence that is larger, more neurological and genetically new at once — three things that are easier to measure together than to disentangle.

This article is informational and is not medical advice.